LHC Group Inc
F:LH6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (4.1), the stock would be worth €61.59 (6 939% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | €0.88 |
0%
|
| 3-Year Average | 4.1 | €61.59 |
+6 939%
|
| 5-Year Average | 4.1 | €61.59 |
+6 939%
|
| Industry Average | 27.6 | €414.23 |
+47 241%
|
| Country Average | 22.9 | €343.33 |
+39 138%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
€27.2m
|
/ |
Jan 2026
$538.5m
|
= |
|
|
€27.2m
|
/ |
Dec 2026
$8.3m
|
= |
|
|
€27.2m
|
/ |
Dec 2027
$10.3m
|
= |
|
|
€27.2m
|
/ |
Dec 2028
$11.2m
|
= |
|
|
€27.2m
|
/ |
Dec 2029
$25.8m
|
= |
|
|
€27.2m
|
/ |
Dec 2030
$33.2m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
L
|
LHC Group Inc
F:LH6
|
26.7m EUR | 0.1 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
106.6B USD | 60.3 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
71B EUR | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
77B USD | 12.9 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.3B EUR | 18.2 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.5B EUR | 22.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21B USD | 20.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.1B USD | 24.1 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.6B EUR | 10.9 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | -26.2 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 14 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
LHC Group Inc
Glance View
In the heart of Lafayette, Louisiana, LHC Group Inc. carved a niche in the labyrinthine healthcare sector with a singular focus: providing quality home health care. Founded in 1994, the company matured into one of the nation's preeminent providers of home health and hospice services. The company's operations are multifaceted, encompassing home health, hospice, and long-term acute care services, as well as healthcare innovations through partnerships with hospitals. With a patient-first mantra, LHC Group captures the essence of healthcare evolution by delivering personalized care directly to the doorsteps of those in need. Their comprehensive offerings include skilled nursing, physical therapy, and in-home aide services, sustained by a decentralized structure that ensures each local agency operates with an adept understanding of community-specific needs. Revenue streams flow primarily from Medicare and Medicaid reimbursements, alongside private insurance and out-of-pocket payments, creating a diverse financial portfolio. The fragmented nature of the home healthcare sector presents LHC Group with unique growth opportunities through acquisitions and strategic partnerships. By aligning with hospitals and health systems, LHC Group not only expands its service reach but also enhances efficiencies in patient care transitions. This synergy not only boosts patient satisfaction through reduced hospital readmissions but also strengthens the company’s financial resilience. The ability to navigate regulatory landscapes and adapt to shifting demographics underscores LHC Group’s role as a key player in shaping the future of home healthcare in America.